CRSP Stock Forecast: CRISPR Therapeutics AG Price Predictions for 2026-2027

Last close, 20 Nov 2026
$39
+0.59% on the day

The 23 Wall Street analysts covering CRISPR Therapeutics AG hold a median 12-month price target of $80 — +104.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 33 of 100 as at 21 Nov 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$3.8B
Ticker Nerd rank
33/ 100
Median analyst target
$80
Analysts covering
23
Revenue$10.0M
Operating income−$117.3M
Net income−$91.2M
Free cash flow−$86.6M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−7.3%
1M
−21.5%
YTD
−25.3%
1Y
−20.6%
From 52W high
−36.7%
From 52W low
+0.6%
$39
$62
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores CRISPR Therapeutics AG on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
33/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
67
Growth
67
Volatility
66
Accruals
54
Quality
43
Momentum
40
Revisions
38
Issuance
14

Value (67): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Issuance (14): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

CRSP stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CRSP, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$50$100$150$200$250$300Jan 26Apr 26Jul 26Oct 26CRSPHigh $291Median $80Low $44

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says23 analysts
13
Buy
10
Hold
0
Sell
$44
Low
$80
Median
$291
High

The green dot is the last close — the median target sits +104.3% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 2 moved their price target up and 1 moved it down.

DateFirmActionRatingTarget
4 Nov 2026CitigroupMaintainsBuy$88 → $90
4 Nov 2026Wells FargoMaintainsEqual-Weight$75 → $70
3 Nov 2026NeedhamReiteratesBuy$82
15 Oct 2026UBSInitiatesNeutral$52
31 Aug 2026CitizensReiteratesMarket Outperform$80
31 Aug 2026NeedhamReiteratesBuy$82
25 Aug 2026CitizensReiteratesMarket Outperform$80
4 Aug 2026CitigroupMaintainsBuy$82 → $88
8 July 2026HC Wainwright & Co.ReiteratesBuy$80
6 July 2026CitizensReiteratesMarket Outperform$80
13 May 2026BernsteinMaintainsMarket Perform—
6 May 2026CitigroupMaintainsBuy—
17 Mar 2026Piper SandlerReiteratesOverweight—
17 Feb 2026Chardan CapitalMaintainsBuy—
13 Feb 2026Evercore ISI GroupMaintainsOutperform—
13 Feb 2026NeedhamMaintainsBuy—
13 Feb 2026TD CowenMaintainsHold—
30 Jan 2026CitizensMaintainsMarket Outperform—
23 Dec 2025CitizensReiteratesMarket Outperform—
23 Dec 2025NeedhamReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for CRSP.

Market Radar

This page is one stock. Monday covers all of them.

CRSP appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

CRSP vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, CRISPR Therapeutics AG returned −20.6% against +6.9% for the S&P 500, dividends included.

CRSP vs S&P 500, last 12 monthsTotal return, rebased to 100
8090100110120130Jan 26Apr 26Jul 26Oct 26CRSPS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

CRSP analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
6
Analysts cutting
9
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
153.3×

Cheaper than 3% of US stocks

Price / book
2.3×

Cheaper than 38% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
1325.1%

Higher than 99% of US stocks

Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−25.6%

Higher than 30% of US stocks

Return on assets
−13.5%

Higher than 24% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • CRISPR Therapeutics AG has a market value of $3.8B and an enterprise value of $2.3B.

  • Revenue in the twelve months to 30 June 2026: $11.0M.

  • Net income over the same four quarters: −$451.1M, a −4101.3% net margin.

  • Diluted earnings per share, trailing twelve months: −$4.76.

  • Free cash flow in the twelve months to 30 June 2026: −$373.8M.

  • Shares outstanding: 96.7M.

  • CRISPR Therapeutics AG employs 393 people — $28K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 20 Nov 2026

Data provided by Twelve Data

Peers

CRSP and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
CRSPCRISPR Therapeutics AG$3.8B33
DFTXDefinium Therapeutics, Inc.$3.9B50
TARSTarsus Pharmaceuticals, Inc.$3.6B72
TNGXTango Therapeutics, Inc.$3.5B23
XENEXenon Pharmaceuticals, Inc.$3.5B41
RLAYRelay Therapeutics, Inc.$3.5B80
PBLSParabilis Medicines, Inc.$3.4B2

Take a look at CRSP’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own CRISPR Therapeutics AG — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about CRSP

What is the CRSP stock price forecast for 2026-2027?

The 23 Wall Street analysts covering CRISPR Therapeutics AG have a median 12-month price target of $80, with estimates ranging from $44 to $291. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CRSP stock a buy right now?

Of the 23 analysts covering CRISPR Therapeutics AG, 13 rate it a Buy, 10 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks CRISPR Therapeutics AG 33 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CRSP?

As at 21 Nov 2026, CRISPR Therapeutics AG ranks 33 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Value (67 of 100).

Will CRSP stock go up?

No one can know that. What the data says: the median 12-month target from 23 analysts implies +104.3% from the last close, and Ticker Nerd's factor model ranks CRISPR Therapeutics AG 33 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CRSP stock forecast for 2030?

No analyst covering CRISPR Therapeutics AG publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CRSP are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $44 to $291 over the next 12 months.

How has CRSP stock performed over the past year?

CRISPR Therapeutics AG returned -20.6% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does CRISPR Therapeutics AG do?

CRISPR Therapeutics AG is a biotechnology company developing gene-based medicines for serious diseases through its CRISPR/Cas9 gene-editing platform. Its work includes ex vivo therapies, in which a patient’s cells are edited outside the body before reinfusion, and in vivo approaches designed to modify genetic targets directly within the body.

Company

About CRISPR Therapeutics AG.

CRISPR Therapeutics AG is a biotechnology company developing gene-based medicines for serious diseases through its CRISPR/Cas9 gene-editing platform. Its work includes ex vivo therapies, in which a patient’s cells are edited outside the body before reinfusion, and in vivo approaches designed to modify genetic targets directly within the body. The company’s current portfolio spans blood disorders, oncology, autoimmune diseases, cardiovascular conditions, and type 1 diabetes. Its leading therapy, CASGEVY, is a gene-edited cell therapy for transfusion-dependent beta-thalassemia and severe sickle cell disease that edits blood-forming stem cells to support production of fetal hemoglobin. CRISPR Therapeutics AG also develops allogeneic CAR T-cell programs intended to address cancer and autoimmune indications, alongside gene-editing candidates targeting cardiovascular risk factors and stem-cell-derived therapies for diabetes. Headquartered in Zug, Switzerland, the company operates at the intersection of biotechnology, cell therapy, and precision medicine, contributing to the development of treatments that address disease at the genetic or cellular level.

CEO Dr. Samarth Kulkarni Ph.D. · 393 employees · Switzerland · https://www.crisprtx.com